GreyBird Ventures

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

Platomics is a Vienna-based company focused on regulatory automation and the development of digital in vitro diagnostic medical devices. The company offers the PlatoX platform, a secure cloud-based system that provides innovative software solutions and facilitates the exchange of information, products, and services within the in vitro diagnostics (IVD) industry. Platomics specializes in creating high-performance analysis services for genetic testing, which assist laboratories and manufacturers in achieving compliance and efficiency. The platform integrates internal quality processes to streamline the creation, execution, and evaluation of genetic tests, ultimately enabling clients to simplify and accelerate their operations through automation.

Angstrom Bio is a biotechnology company focused on developing advanced diagnostic technologies for the accurate and frequent testing of COVID-19 and respiratory pathogens. The company utilizes nanopore sequencing, a technique that employs a machine learning-powered platform to count individual DNA molecules as they pass through nano-scale pores in a specialized membrane. This innovative approach aims to enhance testing accuracy while reducing patient discomfort and minimizing disruption to healthcare organizations. By leveraging novel nucleotide chemistry and machine learning, Angstrom Bio seeks to improve the study, diagnosis, and treatment of various diseases.

GNA Biosolutions is a molecular technology company located in Martinsried, Germany, specializing in innovative diagnostic devices for detecting and analyzing DNA. Their core technology, Pulse Controlled Amplification, enhances molecular testing by integrating ultrafast nucleic acid amplification with intrinsic sample preparation. This advancement allows for efficient and simplified diagnosis of human pathogens in laboratory settings, as well as on-site applications and Point of Care scenarios. GNA Biosolutions aims to make the benefits of molecular testing accessible to a broader audience, facilitating rapid and accurate results from sample collection to analysis.

Jiangxi Zhongke Jiufeng Wisdom Medical Technology Co., Ltd. was established in May 2015. Under the strong support of the Jiangxi Provincial Party Committee Government, Nanchang Municipal Government and the High-tech Zone Government, the former Siemens Northeast Asia (Greater China + Korea) Medical Mr. Wu Wenhui, the president, led the team of domestic and international first-class science and technology experts, hospital management experts and industry senior professional managers.

Ceres Nanosciences Inc. is a privately held life sciences company focused on the development and commercialization of innovative sample preparation products utilizing its proprietary Nanotrap® technology. This technology captures, enriches, and preserves analytes and biomarkers, which is essential for the early detection of diseases such as cancer, cardiac conditions, and infectious diseases. By facilitating the identification of low abundance biomarkers, Ceres aims to enhance diagnostic accuracy and improve patient outcomes while potentially reducing healthcare costs. The company has a diverse product pipeline that includes advanced sample collection technologies and diagnostics, supported by federal grants and industry collaborations. Among its key developments is a direct antigen test for Lyme disease, which is anticipated to be available for commercial use.

Atlas5D, Inc. specializes in developing and manufacturing innovative sensors that assess brain, neuromuscular, and cardiovascular conditions in individuals with reduced mobility. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company offers Echo5D, an ambient sensor that passively measures human movement and behavior without the need for wearable devices. This technology provides continuous monitoring of patient ambulation and dexterity, allowing caregivers and clinicians to gain valuable insights into patients' conditions. Echo5D is particularly beneficial for a diverse range of individuals, including those with conditions such as multiple sclerosis and Parkinson's. By facilitating the tracking of symptom progression and response, Atlas5D empowers users to maintain their independence and enhance their quality of life. The founders of Atlas5D are MIT graduates with backgrounds in consulting and healthcare, and the company has participated in prestigious accelerators, including MassChallenge and TechStars.

Hummingbird Diagnostics GmbH specializes in developing innovative diagnostics aimed at early disease detection, personalized medicine, and health monitoring through the analysis of miRNA biomarkers found in blood. The company provides a range of services, including extraction, microarray, panel development, validation, and bioinformatics, to support the utilization of these biomarkers. Founded in 1998 and based in Heidelberg, Germany, Hummingbird Diagnostics is a subsidiary of febit holding GmbH. The company's mission focuses on leveraging blood-borne miRNAs to understand the immune system's response to diseases, particularly in providing targeted diagnostic tests for late-stage non-small cell lung cancer patients who may benefit from immunotherapy, thereby offering actionable clinical guidance for healthcare providers.